Deal Watch: Bausch Health Takes Option To Allegro Dry AMD Candidate

 
• By Joseph Haas, Alexandra Shimmings, and Brian Yang

Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.

DealWatch_1200x675

More from Deals

More from Business